According to a new research report “Sarcopenia Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, sarcopenia therapeutics currently exhibits a proliferating pipeline with 10+ therapeutic candidates.
Sarcopenia Therapeutics Pipeline Insights
Sarcopenia is a disease related to muscle loss, due to the natural aging process. The disease aggravates after 70 years of age. Loss of muscle and body strength affects the overall balance and ability to perform day-to-day tasks of a person. Sarcopenia is expected to affect physically inactive people more than those who are physically active. Some of the factors responsible for onset of the disease include low concentration of certain hormones, reduction in nerve cells, and absence of necessary calories or proteins.
The disease can be diagnosed by computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, handgrip strength test, usual gait speed test, and others. Furthermore, hormone replacement therapy (HRT) and urocortin II are the off-label medications prescribed for the treatment of sarcopenia as there are no approved medications for sarcopenia. Moreover, exercises such as strength training and resistance training can also avoid sarcopenia.
Insights into Pipeline Segments
According to the research findings, majority of pipeline drug candidates are being developed for intravenous route of administration. In this route of administration, entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug.
Positive Clinical Trial Results are Expected to Drive Sarcopenia Therapeutics Pipeline
Companies that are involved in developing therapeutics for sarcopenia have shown positive results of clinical trials. For instance, results of phase II trial of bimagrumab were published by Novartis AG in September 2017. The results stated that the treatment with bimagrumab over 16 weeks increased muscle mass and strength in older adults with sarcopenia and improved mobility in those who have slow walking speed.
Increasing Investments Play a Pivotal Role in the Sarcopenia Therapeutics Development
Companies are actively seeking funds in order to speed up the drug development process. With increasing investments, the sarcopenia therapeutics development is expected to rise in the near future. For instance, in October 2017, a Paris-based company, Biophytis SAS, garnered around $12 million (EUR 10.4 million) from private placement to start trials of sarcopenic obesity candidates, Sarconeos (BIO101) and Macuneos (BIO201), for dry age-related macular degeneration (AMD).
Browse report overview with detailed TOC on "Sarcopenia Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.pharmaproff.com/report/sarcopenia-therapeutics-pipeline-analysis
Novartis AG, Biophytis SAS, Merck & Co. Inc., and Vibe Pharmaceuticals LLC are some of the major companies involved in development of therapeutics for sarcopenia.
Sarcopenia Therapeutics Pipeline Analysis
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of sarcopenia. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the sarcopenia therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to sarcopenia.